Trabedersen, a TGFβ2-specific antisense oligonucleotide for the treatment of malignant gliomas and other tumors overexpressing TGFβ2

IDrugs

Volumn 12, Issue 7, 2009, Pages 445-453

  Valliéres, Luc ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AP 11014; AP 12009; BELAGENPUMATUCEL L; CARMUSTINE; GC 1008; LOMUSTINE; LY 2157299; PROCARBAZINE; RANAGENGLIOTUCEL T; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; VINCRISTINE; NUCLEOTIDE; OLIGODEOXYRIBONUCLEOTIDE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASTROCYTOMA; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONTINUOUS INFUSION; DRUG ACCUMULATION; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EX VIVO STUDY; GLIOBLASTOMA; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MULTIPLE CYCLE TREATMENT; NONHUMAN; PANCREAS CANCER; PATENT; PROTEIN EXPRESSION; RASH; REVIEW; SKIN CANCER; SOLID TUMOR; SURVIVAL TIME; THROMBOCYTOPENIA; VALIDATION PROCESS; ANIMAL; ARTICLE; BRAIN TUMOR; DRUG ANTAGONISM; DRUG SCREENING; GLIOMA; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; GLIOMA; HUMANS; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; THIONUCLEOTIDES; TRANSFORMING GROWTH FACTOR BETA2;

EID: 68149094346     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. 239122 Eradication of established intracranial rat gliomas by transforming growth factor βantisense gene therapy. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE PROC NATL ACAD SCI USA 1996 937 2909-2914
2. 248676 CpG motifs in bacterial DNA trigger B-cell activation. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretsky GA, Klinman DM NATURE 1995 3746522 546-549
3. 384037 Genzyme General and Cambridge Antibody Technology to collaborate on development of human anti-TGF-β monoclonal antibodies. Genzyme General PRESS RELEASE 2000 September 28
4. 409706 A phase I/II dose escalation study to evaluate the safety and tolerability of phosphorothioate TGF-β2 antisense oligonucleotides in patients with malignant glioma. Hau P, Zellner A, Bogdahn U, Schulmeyer F, Bele S, Brawanski A, Brysch W, Goldbrunner M, Jachimczak P, Kunst M, Schlingensiepen R et al PROC AM SOC CLIN ONCOL 2001 20Pt 2 Abs 2066
5. 444180 TGF-β-specific antisense oligonucleotides enhance activity of monocyte-derived dendritic cells in a glioma model in vitro. Fabel K, Jachimczak P, Miebach R, Apfel R, Tschertner I, Schlingensiepen KH, Brysch W, Bogdahn U PROC AM ASSOC CANCER RES 2001 42Abs 129
6. 444182 Inhibition of TGF-β2 expression in malignant gliomas with antisense oligonucleotides. Jachimczak P, Hau P, Zellner A, Apfel R, Schulmeyer F, Kunst M, Schlingensiepen R, Brysch W, Schlingensiepen KH, Bogdahn U J CANCER RES CLIN ONCOL 2001 127Suppl 1 Abs IM10
7. 541743 TGF-β-2 antisense oligonucleotide AP12009 administered intratumorally to patients with malignant glioma in a clinical phase I/II dose escalation study: Safety and preliminary efficacy data. Hau P, Bogdahn U, Schulmeyer F, Brawanski A, Steinbrecher A, Zellner A, Goldbrunner M, Jachimczak P, Kunst M, Stauder G, Schlingensiepen KH et al PROC AM SOC CLIN ONCOL 2002 211 Abs 109
8. 542976 A clinical phase I/II dose escalation study with TGF-β-2 antisense oligonucleotide AP 12009 administered intratumorally in patients with malignant glioma: Safety and first efficacy data. Hau P, Bogdahn U, Schulmeyer F, Brawanski A, Steinbrecher A, Zellner A, Stauder G, Goldbrunner M, Jachimczak P, Kunst M J CANCER RES CLIN ONCOL 2002 128Suppl 1 Abs O480
9. 543053 Safety pharmacology and toxicity studies of the TGF-β-2 antisense oligonucleotide AP 12009. Stauder GM, Schlingensiepen R, Goldbrunner M, Bischof A, Kurnst M, Schulmeyer F, Jachimczak P, Schlingensiepen KH PROC AM SOC CLIN ONCOL 2002 211 Abs 1897
10. 491561 A TGF-β2 specific antisense oligonucleotide (AP12009) as continuous intratumoral treatment of recurrent high-grade glioma patients: A clinical phase I/II extension study. Stauder GM, Hau P, Bogdahn B, Steinbrecher A, Brawanski A, Schlaier J, Wurm G, Pichler J, Kunst M, Schlingensiepen KH PROC AM SOC CLIN ONCOL 2003 22Abs 436
11. 493161 Preclinical efficacy data as basis for clinical studies with the TGF-β 2 specific antisense oligonucleotide AP 12009 in the treatment of pancreatic cancer. Jachimczak P, Stauder G, Schlingensiepen R, Goldbrunner M, Graf K, Kielmanowicz M, Bischof A, Hafner M, Schlingensiepen KH PROC AM SOC CLIN ONCOL 2003 22Abs 954
12. 496943 Intratumoral treatment of high-grade glioma with a TGF-β-2 antisense oligonucleotide (AP12009): Safety and first efficacy data of a clinical phase I/II dose escalation study. Hau P,Bogdahn U, Grauer O, Jauch T, Schulmeyer F, Schlaier J, Brawanski A, Mehdorn M, Hamel W, Strege R, Stauder G et al PROC AM ASSOC CANCER RES 2003 441st Ed Abs 5361
13. 496952 Suppression of TGF-β 2 in pancreatic cancer by the antisense oligonucleotide AP 12009: In vitro efficacy data. Schlingensiepen KH, Jachimczak P, Graf K, Kielmanowicz M, Schiller W, Hafner M, Bischof A, Stauder G, Schlingensiepen R PROC AM ASSOC CANCER RES 2003 441st Ed Abs 6363
14. 531445 TGF-β 2 suppression by the antisense oligonucleotide AP 12009 as therapy for high-grade glioma: Safety and efficacy resultsof phase I/II clinical studies. Bogdahn U, Hau P, Brawanski A, Schlaier J, Mehdorn M, Nabavi A, Wurm G, Pichler J, Kunst M, Goldbrunner M, Stauder G et al PROC AM ASSOC CANCER RES 2004 45Abs 5239
15. 531794 TGF-β 2 suppression in pancreatic cancer by the antisense oligonucleotide AP 12009: Preclinical efficacy data. Schlingensiepen KH, Stauder G, Bischof A, Egger T, Hafner M, Herrmuth H, Kielmanowicz M, Jachimczak P PROC AM ASSOC CANCER RES 2004 45Abs 2955
16. 541034 Specific therapy for high-grade glioma by convection-enhanced delivery of the TGF-β 2 specific antisense oligonucleotide AP 12009. Bogdahn U, Hau P, Brawanski P, Schlaier J, Mehdorn M, Wurm G, Pichler J, Kunst M, Stauder G, Schlingensiepen KH PROC AM SOC CLIN ONCOL 2004 40Abs 1514
17. 542888 TGF-β 2 suppression by the antisense oligonucleotide AP 12009 as treatment for pancreatic cancer: Preclinical efficacy data. Stauder G, Bischof A, Egger T, Hafner M, Herrmuth H, Jachimczak P, Kielmanowicz M, Schlingensiepen R, Schlingensiepen KH J CLIN ONCOL 2004 2214S Abs 4106
18. 564540 TGF-β 2 suppression by the antisense oligonucleotide AP 12009 as therapy for high-grade glioma: Safety and efficacy results of phase I/II clinical studies. Schlingensiepen K, Hau P, Brawanski A, Schlaier J, Mehdorn M, Wurm G, Pichler J, Kunst M, Stauder G, Bogdahn U EJC SUPPL 2004 28 Abs 439
19. 564541 Treatment of pancreatic cancer by TGF-β 2 suppression mediated by the antisense oligonucleotide AP 12009: Preclinical efficacy data. Stauder G, Bischof A, Egger T, Hafner M, Herrmuth H, Kielmanocwicz M, Jachimczak P, Schlingensiepen R, Schlingensiepen K EJC SUPPL 2004 28 Abs 449
20. 584622 Antisense Pharma opens phase I/II study of anticancer oligonucleotide. Antisense Pharma GmbH PRESS RELEASE 2005 February 10
21. 593553 Simultaneous reversal of immunosuppression, inhibition of tumor growth and migration by the TGF-β 1 antisense oligonucleotide AP 11014 in prostatic, colorectal and non-small cell lung cancer. Fischer D, Bischof A, Egger T, Hafner M, Herrmuth H, Jachimczak P, Kielmanowicz M, Stauder G, Schlingensiepen KH PROC AM ASSOC CANCER RES 2005 46Abs 592
22. 596264 The TGF-β 2 antisense oligonucleotide AP 12009 as a therapeutic agent in pancreatic cancer: Evaluation of the safety and tolerability in a phase I/II dose escalation study. Schlingensiepen KH, Bischof A, Fischer D, Egger T, Hafner M, Herrmuth H, Kielmanowicz M, Ludwig S, Schmaus S, Stauder G PROC AM ASSOC CANCER RES 2005 46Abs 3351
23. 635815 Targeted downregulation of TGF-β 2 by the antisense compound AP 12009 as immunotherapy for malignant glioma: A phase IIb study. Schlingensiepen KH, Kunst M, Pichler J, Parfenov VE, Sastry KVR, Zaaroor M, Rappaport ZH, Hau P, Schlingensiepen R, Bogdahn U CLIN CANCER RES 2005 1123 suppl Abs C79
24. 68567 Phase I/II-trial expanded: TGF-β 2-inhibitor AP 12009 for colorectal carcinoma and malignant melanoma patients. Antisense Pharma GmbH PRESS RELEASE 2006 May 18
25. 669073 Results of G004, a phase IIb study in recurrent glioblastoma patients with the TGF-β 2 targeted compound AP 12009. Bogdahn U, Oliushine VE, Parfenov VE, Kunst M, Mahapatra A, Sastry KV, Venkataramana KN, Jachimczak P, Hau P, Schlingensiepen K J CLIN ONCOL 2006 2418S Abs 1553
26. 668092 Results of G004, a phase IIb actively controlled clinical trial with the TGF-β 2 targeted compound AP 12009 for recurrent anaplastic astrocytoma. Hau P, Stockhammer G, Kunst M, Mahapatra A, Sastry KV, Parfenov VE, Leshinsky VG, Jachimczak P, Bogdahn U, Schlingensiepen K J CLIN ONCOL 2006 2418S Abs 1566
27. 671306 Suppression of TGF-β 2 in pancreatic cancer by the antisense oligonucleotide AP 12009: Preclinical efficacy data as basis for clinical studies. Stauder G, Jachimczak P, Schlingensiepen R, Goldbrunner M, Graf K, Kielmanowicz M, Hafner M, Szyrach M, Bischof A, Schlingensiepen KH EJC SUPPL 2003 15 Abs 229
28. 671313 Targeted down regulation of TGF-β 2 in pancreatic carcinoma: A phase I/II dose escalation study to evaluate the safety and tolerability of the antisense oligonucleotide AP 12009. Schlingensiepen KH, Bischof A, Egger T, Hafner M, Herrmuth H, Kielmanowicz M, Ludwig S, Schmaus S, Stauder G J CLIN ONCOL 2005 2316S Abs 1537
29. 671315 Targeted downregulation of TGF-β 2 as immunotherapy for high-grade glioma: A phase IIb study. Hau P, Kunst M, Pichler J, Parfenov VE, Sastry KVR, Spitznagel L, Zaaroor M, Bogdahn U, Schlingensiepen KH J CLIN ONCOL 2005 2316S Abs 1537
30. 671318 Preclinical efficacy data on TGF-β 2 suppression in pancreatic cancer by the antisense oligonucleotide AP 12009. Stauder G, Bischof A, Egger T, Hafner M, Herrmuth H, Kielmanowicz M, Jachimczak P, Schlingensiepen KH J CANCER RES CLIN ONCOL 2004 130Suppl1 Abs OP686
31. 671320 The TGF-β 2 antisense oligonucleotide AP 12009 as a therapeutic agent in recurrent high-grade glioma: Safety and efficacy results of phase I/II clinical trials. Hau P, Bogdahn U, Schlaier J, Mehdorn M, Wurm G, Pichler J, Kunst M, Goldbrunner M, Schlingensiepen KH, Stauder G EJC SUPPL 2003 15 Abs 34
32. 671324 Antisense-TGF-β -2 oligonucleotide AP 12009: Results of safety pharmacology and toxicity studies. Schlingensiepen R, Goldbrunner M, Bischof A, Kunst M, Schulmeyer F, Jachimczak P, Stauder G, Schlingensiepen KH J CANCER RES CLIN ONCOL 2002 128Suppl 1 Abs P673
33. 671327 Intracerebral and intrathecal infusion of the TGF-β 2-specificantisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: Toxicology and safety. Schlingensiepen R, Goldbrunner M, Szyrach MNI, Stauder G, Jachimczak P, Bogdahn U, Schulmeyer F, Hau P, Schlingensiepen KH OLIGONUCLEOTIDES 2005 152 94-104. A preclinical safety and toxicity study demonstrating that trabedersen can be administered chronically to rabbits, rats and monkeys via the intracerebral or intravenous route without causing major side effects.
34. 671328 TGF-β 2 suppression by the antisense oligonucleotide AP 12009 as therapy for high-grade glioma: Safety and efficacy results of phase I/II clinical studies. Bogdahn U, Hau P, Brawanski A, Schlaier J, Mehdorn M, Nabavi A, Wurm G, Pichler J, Goldbrunner M, Kunst M, Stauder G et al NEUROLOGY2004 627 Suppl 5 Abs S67.001
35. 671331 Safety and efficacy results of phase I/II clinical studies for therapy of high-grade glioma by TGF-β 2 suppression mediated by the antisense oligonucleotide AP 12009. Hau P, Bogdahn U, Brawanski A, Schlaier J, Mehdorn M, Nabavi A, Wurm G, Pichler J, Kunst M, Stauder G J CANCER RES CLIN ONCOL 2004 130Suppl 1 Abs OP474
36. 671332 Targeted tumor therapy with the TGF-β2 antisense compound AP 12009. Schlingensiepen KH, Schlingensiepen R, Steinbrecher A, Hau P, Bogdahn U, Fischer-Blass B, Jachimczak P CYTOKINE GROWTH FACTOR REV 2006 171-2 129-139. Review of preclinical and phase I/II clinical trials presenting significant data from clinical trials for glioma, pancreatic cancer and malignant melanoma. A summary of phase I/II dose-escalation trials in patients with astrocytoma revealed the median survival rate after treatment with trabedersen to be 146.6 weeks for patients with grade III astrocytoma and 44.0 weeks for patients with grade IV astrocytoma.
37. 739573 A phase IIb study in patients with recurrent malignant glioma with the TGF-β2 inhibitor AP 12009. Bogdahn U, Zaaroor M, Parfenov V, Kunst M, Mahapatra AK, Sastry KVR, Jachimczak P, Stockhammer G, Rappaport ZH, Schlingensiepen KH EUR J CANCER 2006 412 Abs 329
38. 796201 Preliminary results of a phase I/II study in pancreatic carcinoma, malignant melanoma, and colorectal carcinoma with the TGF-β2 inhibitor AP 12009. Oettle H, Seufferlein T, Schmid R, Luger T, Ludwig S, Schmaus S, Wuerth G, Heinrichs H, Schlingensiepen K J CLIN ONCOL 2007 2518S Abs 4607
39. 796986 A phase IIb actively controlled study with the TGF-β -2 inhibitor AP 12009 for recurrent or refractory anaplastic astrocytoma. Bogdahn U, Mahapatra A, Olyushin VE, Mouli C, Parfenov VE, Stockhammer G, Ludwig S, Wuerth G, Heinrichs H, Schlingensiepen K J CLIN ONCOL 2007 2518S Abs 2025
40. 911052 Targeted therapy with AP 12009 in recurrent or refractory glioblastoma patients: Results of a phase IIb study. Bogdahn U, Hau P, Olyushin V, Mahapatra AK, Parfenov V, Venkataramana NK, Wassmann H, Ludwig S, Heinrichs H, Schlingensiepen KH J CLIN ONCOL 2008 26May 20 Abs 2018
41. 9111932 Results of a phase IIb active-controlled study with AP 12009 for patients with recurrent or refractory anaplastic astrocytoma. Bogdahn U, Mahapatra AK, Olyushin V, Parfenov V, Stockhammer G, Ludwig S, Wuerth G, Heinrichs H, Schlingensiepen KH J CLIN ONCOL 2008 26May 20 Abs 2076
42. 913261 Preliminary results of a phase I/II study in patients with pancreatic carcinoma, malignant melanoma, or colorectal carcinoma using systemic i.v. administration of AP 12009. Hilbig A, Seufferlein T, Schmid RM, Luger T, Oettle H, Schneider G, Schmaus S, Wuerth G, Heinrichs H, Schlingensiepen KH J CLIN ONCOL 2008 26May 20 Abs 4621
43. 916452 RNAi, siRNA, miRNA 2008 - SMi's third annual conference, London, UK. Jago C IDDB MEETING REPORT 2008 June 11-12
44. 917051 Cancer statistics, 2008. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ CA CANCER J CLIN 2008 582 71-96
45. 935930 Company website: Genzyme. Genzyme Corp COMPANY WORLDWIDE WEB SITE 2008 August 18
46. 968485 NovaRx appoints industry veteran as president and COO. NovaRx Corp PRESS RELEASE 2008 December 04
47. 993983 TGF-β 2 antisense oligonucleotide AP 12009 (trabedersen) as a therapeutic agent in colorectal cancer. Jaschinski F, Rothhammer T, Fischer D, Kick C, Kielmanowicz M, Jachimczak P, Schlingensiepen KH AM ASSOC CANCER RES ANN MEET 2009 100Abs 845
48. 995473 Targeted tumor therapy with the TGF-β 2 antisense compound AP 12009 for the treatment of advanced solid tumors. Oettle H, Seufferlein T, Schmid R, Luger T, Ludwig S, Schmaus S, Beyer M, Fischer D, Hafner M, Schlingensiepen K J CLIN ONCOL 2006 2418S Abs 14012
49. 995481 Results of a phase IIb study in recurrent or refractory glioblastoma patients with the TGF-β-2 inhibitor AP 12009. Hau P, Bogdahn U, Olyushin VE, Mahapatra A, Parfenov VE, Venkataramana K, Ludwig S, Jachimczak P, Heinrichs H, Schlingensiepen K J CLIN ONCOL 2007 2518S Abs 12521
50. 995502 Antisense therapeutics for tumor treatment: The TGF-β 2 inhibitor AP 12009 in clinical development against malignant tumors. Schlingensiepen KH, Fischer-Blass B, Schmaus S, Ludwig S RECENT RESULTS CANCER RES 2008 177137-150
51. 995516 Antisense, RNAi, and gene silencing strategies for therapy: Mission possible or impossible? Rayburn ER, Zhang R DRUG DISC TODAY 2008 13513-521
52. 995518 Tumour microenvironment: TGFβ: The molecular Jekyll and Hyde of cancer. Bierie B, Moses HL NAT REV CANCER 2006 6506-520
53. 995534 TGFβ in cancer. Massague J CELL 2008 134215-230
54. 995557 Immunosuppression and transforming growth factor-β in glioblastoma. Preferential production of transforming growth factor-β 2. Bodmer S, Strommer K, Frei K, Siepl C, de Tribolet N, Heid I, Fontana A J IMMUNOL 1989 14310 3222-3229
55. 995558 Expression of TGF-β isoforms, TGF-β receptors, and SMAD molecules at different stages of human glioma. Kjellman C, Olofsson SP, Hansson O, Von Schantz T, Lindvall M, Nilsson I, Salford LG, Sjogren HO, Widegren B. INT J CANCER 2000 893 251-258
56. 995559 High TGFβ -SMAD activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Bruna A, Darken RS, Rojo F, Ocana A, Penuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J, Seoane J CANCER CELL (ONLINE) 2007 112 147-160
57. 995561 Integration of SMAD and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Seoane J, Le HV, Shen L, Anderson SA, Massague J CELL 2004 1172 211-223
58. 995563 RNA interference targeting transforming growth factor-β enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A, Weller M CANCER RES 2004 6420 7596-7603
59. 995568 Microglia-derived TGF-β as an important regulator of glioblastoma invasion - An inhibition of TGF-β -dependent effects by shRNA against human TGF-β type II receptor. Wesolowska A, Kwiatkowska A, Slomnicki L, Dembinski M, Master A, Sliwa M, Franciszkiewicz K, Chouaib S, Kaminska B ONCOGENE 2008 277 918-930
60. 995583 Inhibiting TGF-β signaling restores immune surveillance in the SMA-560 glioma model. Tran TT, Uhl M, Ma JY, Janssen L, Sriram V, Aulwurm S, Kerr I, Lam A, Webb HK, Kapoun AM, Kizer DE et al J NEURO ONCOL 2007 93 259-270
61. 995586 SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A et al CANCER RES 2004 6421 7954-7961
62. 996017 Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Levy L, Hill CS CYTOKINE GROWTH FACTOR REV 2006 171-2 41-58
63. 996018 Development of TGF-β signalling inhibitors for cancer therapy. Yingling JM, Blanchard KL, Sawyer JS NAT REV DRUG DISCOV 2004 312 1011-1022
64. 996019 Pathology and genetics of tumours of the nervous system. PATHOL GENET TUMOURS NERV SYST (EDS: KLEINHUES P, CAVENEE WK) 2000 IARC Press, Lyon, France 2 1-314
65. 996021 Inhibition of TGF-β 2 with AP 12009 in recurrent malignant gliomas: From preclinical to phase I/II studies. Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T, Steinbrecher A, Brawanski A, Proescholdt M, Schlaier J, Buchroithner J, Pichler J et al OLIGONUCLEOTIDES 2007 172 201-212 Demonstrated that trabedersen can reduce the secretion of TGFβ2, cell migration, cell proliferation and TGFβ2-'mduced immunosuppression in tumor cells in culture and exert antitumor effects ex vivo. Trabedersen can be administered safely to patients with malignant astrocytomas using an intracerebral catheter; no life-threatening side effects were observed. Results from a phase I clinical trial in patients with grade III and IV astrocytoma were reported.
66. 996027 The experimental use of antisense oligonucleotides: A guide for the perplexed. Stein CA J CLIN INVEST 2001 1085 641-644
67. 996034 Internucleotide phosphite sulfurization with tetraethylthiuram disulfide. Phosphorothioate oligonucleotide synthesis via phosphoramidite chemistry. Vu H, Hirschbein BL TETRAHEDRON LETT 1991 3226 3005-3008
68. 996036 Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. Srinivasan SK, Iversen P J CLIN LAB ANAL 1995 92 129-137
69. 996042 The effect of transforming growth factor-β 2-specificphosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. Jachimczak P, Bogdahn U, Schneider J, Behl C, Meixensberger J, Apfel R, Dorries R, Schlingensiepen KH, Brysch W J NEUROSURG 1993 786 944-951
70. 996044 Transforming growth factor-β -mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Jachimczak P, Hessdorfer B, Fabel-Schulte K, Wismeth C, Brysch W, Schlingensiepen KH, Bauer A, Blesch A, Bogdahn U INT J CANCER 1996 653 332-337
71. 996048 Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Felnerova D, Viret JF, Gluck R, Moser C CURR OPIN BIOTECHNOL 2004 156 518-529
72. 996050 Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Juliano R, Alam MR, Dixit V, Kang H NUCLEIC ACIDS RES 2008 3612 4158-4171
73. 996052 Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Allard E, Passirani C, Benoit JP BIOMATERIALS 2009 3012 2302-2318
74. 996068 Antisense technology: A selective tool for gene expression regulation and gene targeting. Sahu NK, Shilakari G, Nayak A, Kohli DV CURR PHARM BIOTECHNOL 2007 85 291-304
75. 996070 State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers.Fattal E, Bochot A INT J PHARM 2008 3642 237-248
76. 996073 Creating immune privilege: Active local suppression that benefits friends, but protects foes. Mellor AL, Munn DH NAT REV IMMUNOL 2008 81 74-80
77. 996076 Cancer despite immunosurveillance: Immunoselection and immunosubversion. Zitvogel L, Tesniere A, Kroemer G NAT REV IMMUNOL 2006 610 715-727
78. 996077 Immunosuppressive networks in the tumour environment and their therapeutic relevance. Zou W NAT REV CANCER 2005 54 263-274
79. 996078 Galectins as modulators of tumour progression. Liu FT, Rabinovich GA NAT REV CANCER 2005 51 29-41
80. 998692 Statistical report: Primary brain tumors in the United States, 2000-2004. Central Brain Tumor Registry of the United States INTERNET SITE 2008 December 31
81. 998753 Transforming growth factor-β 2 is a molecular determinant for site-specific melanoma metastasis in the brain. Zhang C, Zhang F, Tsan R, Fidler IJ CANCER RES 2009 693 828-835
82. 998757 Melanoma-associated expression of transforming growth factory isoforms. Van Belle P, Rodeck U, Nuamah I, Halpern AC, Elder DE AM J PATHOL 1996 1486 1887-1894
83. 998759 Altered expression of TGFβ receptors and mitogenic effects of TGFβ in pancreatic carcinomas. Jonson T, Albrechtsson E, Axelson J, Heidenblad M, Gorunova L, Johansson B, Hoglund M INT J ONCOL 2001 191 71-81
84. 998760 Differential expression of transforming growth factors-β 1, -β 2 and -β3 in human colon carcinoma. Bellone G, Carbone A, Tibaudi D, Mauri F, Ferrero I, Smirne C, Suman F, Rivetti C, Migliaretti G, Camandona M, Palestro G et al EUR J CANCER 2001 372 224-233
85. 998766 International nonproprietary names for pharmaceutical substances (INN). WHO WHO DRUG INF 2007 212 133-190
86. 1000414 Selection bias in clinical trials. Miller KD, Rahman ZU, Sledge GW Jr BREAST DIS 2001 1431-40
87. 1000416 Pitfalls and biases in the reporting and interpretation of the results of clinical trials. Parmar MK LUNG CANCER 1994 10Suppl 1 S143-S150
88. 1003349 Antisense starts phase III trial of trabedersen for anaplastic astrocytoma. Antisense Pharma GmbH PRESS RELEASE 2009 April 27
89. 1003413 Management of single brain metastasis: A practice guideline. Mintz A, Perry J, Spithoff K, Chambers A, Laperriere N CURR ONCOL 2007 144 131-143
90. 1003440 Inhibition of transforming growth factor-β 2 expression with phosphorothioate antisense oligonucleotides in U937 cells. Shen ZJ, Kim SK, Lee YS, Lee JW, Moon BJ BIOORG MED CHEM LETT 1999 913-18
91. 1010734 Mammalian transforming growth factor-β s: SMAD signaling and physio-pathological roles. Javelaud D, Mauviel A INT J BIOCHEM CELL BIOL 2004 367 1161-1165
92. 1003454 Targeting transforming growth factor-β signaling in liver metastasis of colon cancer. Zhang BX, Halder SK, Zhang SG, Datta PK CANCER LETT 2009 2771 114-120
93. 1013345 Chemotherapy side effects fact sheets. National Cancer Institute INTERNET SITE 2009 May 28